Evidence map›Paper›PMID 41909733›Full record

ReviewActa pharmaceutica Sinica. B2026

Membrane-derived biomimetic nanovesicles in anti-tumor immunotherapy: Advances and outlook.

Xianlu Zhang, Hongwei Jing, Yiyang Wang, Siyu Mu, Xia Wang, Haoyuan Zheng, Yiming Chen, Kaiyuan Wang, Jin Sun, Jianbin Bi and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xianlu ZhangDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
Hongwei JingDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
Yiyang WangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Siyu MuDepartment of Neurology, The First Hospital of China Medical University, Shenyang 110000, China.
Xia WangGuangdong Provincial Key Laboratory of Urology, Guangdong Engineering Research Center of Urinary Minimally Invasive Surgery Robot and Intelligent Equipment, Guangzhou Institute of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou 510120, China.
Haoyuan ZhengDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
Yiming ChenDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
Kaiyuan WangDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jin SunDepartment of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Jianbin BiDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.
Gejun ZhangDepartment of Urology, The First Hospital of China Medical University, Shenyang 110000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Membrane-derived biomimetic nanovesicles have emerged as a promising platform in cancer immunotherapy due to their intrinsic biocompatibility, functional plasticity, and capability to modulate immune responses. By integrating various immunotherapeutic agents, including immune checkpoint inhibitors, tumor antigens, and immunostimulatory adjuvants, these vesicles can be engineered to mimic natural immune communication and overcome key barriers in the tumor immune microenvironment. This review summarizes recent advances in the design, functionalization, and application of biomimetic nanovesicles for anti-tumor immunity. We particularly highlight strategies that harness these vesicles to enhance innate and adaptive immune responses, reverse immune suppression, and synergize with existing immunotherapy modalities. Furthermore, we discuss the challenges associated with biosafety, large-scale manufacturing, and clinical translation. Continued innovation in vesicle engineering and immunological modulation will be crucial for transforming biomimetic nanovesicles into viable next-generation cancer immunotherapeutics.

Indexed as

Biomimetic nanovesiclesCancer immunotherapyDrug deliveryExtracellular vesiclesImmune checkpoint inhibitorImmune modulationMembrane engineeringNanovaccine

Identifiers

PMID41909733
PMCPMC13031077

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.